Losartan Cost in Wyoming 2026

Prescription access and medication affordability image for Losartan Cost in Wyoming 2026

At a glance

  • Average cash-pay price / ~$10/month at Wyoming retail pharmacies (2026)
  • Brand-name Cozaar list price / ~$80/month
  • Wyoming Medicaid coverage / Not currently on preferred drug list
  • Compounded losartan via 503A pharmacy / Available in Wyoming; cost often $0/month with qualifying program
  • Telehealth prescribing / Legal and widely available in Wyoming
  • Typical dose / 25 to 100 mg once daily, oral tablet
  • FDA approval year / 1995 (first ARB approved in the US)
  • Key trial / LIFE (Lancet 2002): 13% reduction in composite cardiovascular endpoint vs. atenolol
  • Discount tools / GoodRx, NeedyMeds, Merck patient assistance

What Losartan Is and Why It Matters for Wyoming Patients

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA in 1995 for hypertension, and later for diabetic nephropathy and heart failure with reduced ejection fraction. It works by blocking the AT1 receptor, reducing peripheral vascular resistance and aldosterone secretion. Wyoming has one of the lower population densities in the country, which means pharmacy access and telehealth options carry unusual weight for residents in rural counties like Niobrara, Sublette, and Weston.

The FDA-approved label covers three indications: hypertension, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy, and nephroprotection in type 2 diabetic patients with elevated serum creatinine and proteinuria [1]. Hypertension affects roughly 47% of U.S. adults according to CDC surveillance data, making ARBs like losartan among the highest-volume prescriptions dispensed nationally [2].

In the landmark LIFE trial (N=9,193, Lancet 2002), losartan-based therapy reduced the composite of cardiovascular death, myocardial infarction, and stroke by 13% relative to atenolol-based therapy (RR 0.87; 95% CI 0.77, 0.98; P<0.021), with a particularly pronounced 25% reduction in fatal and non-fatal stroke [3]. That evidence base is why losartan appears on the American Heart Association's hypertension treatment algorithm as a preferred first-line agent for patients with diabetes or chronic kidney disease [4].


How Much Does Losartan Cost in Wyoming in 2026?

Generic losartan costs roughly $10 per month at Wyoming retail pharmacies when purchased cash-pay in 2026. That figure reflects a 50 mg once-daily prescription filled at a 30-day supply with a free GoodRx or similar discount coupon.

Before digging into savings programs, it helps to understand the price layers that exist in the Wyoming market.

Manufacturer list price. Merck's brand Cozaar carries a wholesale acquisition cost near $80 per month for a standard 50 mg supply. Almost no patient pays that price directly, but it sets the ceiling from which insurer and pharmacy benefit manager (PBM) negotiations descend [5].

Generic cash price. Multiple manufacturers now produce generic losartan potassium tablets. At GoodRx contract rates, losartan 50 mg (30 tablets) averages $7, $12 at Wyoming Walmart, Walgreens, Safeway, and independent pharmacies. Cheyenne-area pharmacies and Casper chains tend to cluster near the low end of that range. Smaller towns in Carbon County may sit slightly higher due to limited pharmacy competition, though mail-order generics close that gap.

Compounded losartan. Licensed 503A compounding pharmacies can prepare losartan in customized formulations (different strengths, oral suspensions, or combination preparations not commercially available). For qualifying patients who obtain a valid prescription through a telehealth or in-person visit, compounded losartan through certain patient assistance pathways is available at no direct cost to the patient. The $0/month figure noted in our data applies to specific patient assistance arrangements, not to routine compounding.

The American College of Cardiology's 2017 hypertension guideline recommends initiating therapy for stage 1 hypertension (130, 139/80 to 89 mmHg) when 10-year ASCVD risk reaches 10% or higher, and for all stage 2 hypertension regardless of risk [6]. At $10 per month, losartan's cost is rarely a barrier at the pharmacy counter. The barriers are more often insurance tier placement, prior authorization, or simple awareness of discount tools.


Wyoming Medicaid and Losartan Coverage

Wyoming Medicaid does not currently list losartan on its preferred drug list (PDL). This means Medicaid beneficiaries in Wyoming cannot obtain losartan without a prior authorization approval from Wyoming Department of Health, Division of Healthcare Financing.

That absence from the PDL does not mean losartan is never covered. A prescriber can submit a prior authorization citing medical necessity, particularly if a patient has documented intolerance to ACE inhibitors (such as ACE-inhibitor cough, which occurs in up to 15% of patients) or a specific indication like diabetic nephropathy where ARBs have a superior evidence profile. The RENAAL trial (N=1,513) demonstrated that losartan reduced the risk of doubling serum creatinine, end-stage renal disease, or death by 16% compared to placebo in patients with type 2 diabetes and nephropathy (P<0.022) [7]. That data point is clinically relevant when building a PA argument.

Wyoming Medicaid's current preferred ARBs, if any, tend to be those with the lowest state contract pricing through the National Medicaid Pooling Initiative. If your prescriber believes losartan is medically necessary and a preferred alternative would cause harm, Wyoming Administrative Code Chapter 3 provides a formal appeals pathway. Patients have 90 days from a denial to file.

For dual-eligible patients (Medicare and Medicaid), Medicare Part D typically covers generic losartan in Tier 1 or Tier 2 on most plans. Wyoming had approximately 98,000 Medicare Part D enrollees as of CMS data published in 2024 [8]. Most Part D plans place generic losartan at a $0, $5 copay in Tier 1, making the PDL issue largely irrelevant for dual-eligibles.


Is Compounded Losartan Legal in Wyoming?

Yes. Compounded losartan is legal in Wyoming when prepared by a licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. These pharmacies may prepare losartan in strengths or forms not commercially available (for example, a 12.5 mg oral suspension for a pediatric patient or an elderly patient with swallowing difficulties) provided a prescriber writes an individualized prescription [9]. Wyoming Board of Pharmacy rules require all compounding pharmacies operating within the state, or shipping into Wyoming, to hold a valid Wyoming non-resident pharmacy permit.

503B outsourcing facilities, the larger-scale compounders, operate under separate FDA oversight and may produce losartan without patient-specific prescriptions for hospital or clinic use. For individual outpatient patients, the 503A pathway is the relevant one.

Two conditions must be met for legal compounding under 503A: the drug must not be on the FDA's "demonstrably difficult to compound" list (losartan is not), and a commercially available equivalent should not fully meet the patient's clinical need [10]. A prescriber documenting a clinical rationale (dose customization, excipient allergy, or the need for an oral liquid formulation) satisfies this requirement.

Patients should confirm their compounding pharmacy's Wyoming permit status through the Wyoming Board of Pharmacy license verification portal before filling.


Losartan via Telehealth in Wyoming

Wyoming law allows telehealth prescribing of losartan. The Wyoming Telehealth Act (W.S. 33-26-102 et seq.) permits licensed physicians and advanced practice providers to establish a patient-provider relationship via synchronous audio-video technology and prescribe Schedule-exempt medications including antihypertensives.

Losartan is not a controlled substance. No Wyoming statute requires an in-person visit before prescribing it. A telehealth provider who reviews your blood pressure history, relevant labs (basic metabolic panel to assess renal function and potassium), and current medication list can issue a valid losartan prescription.

The HealthRX clinical intake protocol for losartan via telehealth requires: (1) at-home blood pressure log showing at least two readings on separate days above 130/80 mmHg; (2) most recent serum creatinine and potassium within 12 months; (3) medication reconciliation to screen for concurrent ACE inhibitors (contraindicated combination with losartan due to increased risk of hypotension, hyperkalemia, and renal impairment per FDA labeling); and (4) pregnancy status confirmation, given losartan's FDA Pregnancy Category D designation and its black-box warning against use in pregnancy [1]. After intake, most patients receive a prescription decision within 24 hours.

The FDA's 2023 guidance on telehealth prescribing of non-controlled drugs supports this model and notes that patient safety is not compromised when appropriate screening protocols are followed [11]. Wyoming does not impose additional telemedicine restrictions beyond licensure requirements for non-controlled medications.


Insurance Coverage for Losartan in Wyoming

Most private insurance plans in Wyoming cover generic losartan, typically in Tier 1 or Tier 2 of a formulary.

Wyoming's insurance market includes carriers like Blue Cross Blue Shield of Wyoming, Cigna, Aetna, and UnitedHealthcare operating on ACA marketplace plans, employer group plans, and individual plans. The ACA requires all non-grandfathered plans to cover preventive services without cost-sharing, and while antihypertensive medications are not classified as purely preventive services under USPSTF guidelines, they are consistently placed in low-cost tiers due to generic availability [12].

A standard Tier 1 copay for a 30-day generic supply runs $0, $10. Tier 2 copays in Wyoming ACA silver plans average $15, $30. If your plan places losartan in Tier 3 or higher (uncommon for the generic but possible on narrow-network plans), request a formulary exception in writing. The ACA requires insurers to provide an exception decision within 72 hours for non-urgent requests and 24 hours for urgent cases.

Medicare Part D: The standard Part D deductible in 2026 is $590 [13]. Once satisfied, generic losartan at Tier 1 typically costs $0, $5 per month. Low Income Subsidy (LIS) beneficiaries pay $0, $4.50 for generics under 2026 LIS copay schedules. Wyoming's SHIBA program (State Health Insurance Benefits Advisors) offers free plan comparison help by calling 1-800-856-4398.


The Cheapest Ways to Get Losartan in Wyoming

For most Wyoming residents, cash-pay with a discount coupon at a large-chain pharmacy delivers the lowest total cost.

GoodRx and competitor coupons. GoodRx, RxSaver, and NeedyMeds all list Wyoming pharmacy prices. At Walmart in Cheyenne or Casper, GoodRx codes routinely price losartan 50 mg (30 tablets) at $7, $9. The coupon is free to use and accepted alongside cash payment. Do not use it on the same transaction as insurance, as most pharmacy benefit agreements prohibit stacking.

90-day supply. Filling a 90-day supply instead of 30 days typically cuts the per-pill cost by 10 to 20% at chains like Costco or Sam's Club. Costco Pharmacy in Cheyenne does not require a membership to use the pharmacy, a detail many Wyoming residents miss.

Merck patient assistance. Merck's Helps program (now administered through PAN Foundation partnerships) provides branded Cozaar at no cost to patients below 300% of the federal poverty level who lack adequate coverage. The FPL threshold in 2026 is $47,580 for a household of three [14]. Generic losartan is inexpensive enough that this program is rarely the first choice, but it exists for patients who specifically require the brand.

NeedyMeds. NeedyMeds maintains a database of manufacturer patient assistance programs and 340B-eligible clinics in Wyoming [15]. Federally Qualified Health Centers (FQHCs) in Wyoming, including Cheyenne-based community health centers, dispense medications at 340B discounted prices, which can drop losartan's effective cost below the already-low GoodRx rate.

Mail-order pharmacy. Most Part D and commercial plans offer 90-day mail supplies at a 2-copay cost. For a Tier 1 drug at a $5 copay, that means $10 for a 90-day supply, or about $3.33 per month.


Losartan Dosing and Clinical Use Relevant to Cost Planning

Understanding the approved dose range helps predict monthly cost. FDA-approved dosing is as follows [1]:

  • Hypertension in adults: 25 to 100 mg once daily. Most patients are maintained on 50 mg once daily.
  • Hypertension in pediatric patients aged 6 and older (weight >20 kg): 0.7 mg/kg/day, maximum 50 mg/day.
  • Diabetic nephropathy: 50 mg once daily, titrated to 100 mg once daily based on blood pressure response.
  • Stroke risk reduction (with LVH): 50 mg once daily, with hydrochlorothiazide 12.5 mg added if needed, up to losartan 100 mg.

A patient on 100 mg daily uses two 50 mg tablets, which doubles the pill count but not always the price. At $7, $9 for 30 tablets of 50 mg, a 60-tablet fill for 100 mg/day costs roughly $14, $18 per month at GoodRx prices, still a very low burden [1].

Losartan has a well-characterized adverse effect profile. Hyperkalemia risk increases significantly in patients with eGFR <45 mL/min/1.73m² or baseline potassium above 5.0 mEq/L [16]. The ONTARGET trial (N=25,620) found that combining losartan with ramipril (an ACE inhibitor) increased adverse renal outcomes and hyperkalemia without additional cardiovascular benefit compared to either agent alone, confirming current guideline recommendations against dual RAAS blockade [17].


Monitoring Requirements That Affect Total Cost

Losartan is not a set-and-forget prescription. Two lab parameters require periodic monitoring: serum creatinine (renal function) and serum potassium.

The American Diabetes Association's 2024 Standards of Care recommend checking renal function and electrolytes within 1 to 3 months of initiating an ARB in diabetic patients, and annually thereafter if stable [18]. For non-diabetic hypertensive patients, most guidelines suggest a baseline BMP and a recheck at 4 to 6 weeks after any dose change.

In Wyoming, outpatient BMP testing through a hospital or independent lab runs $20, $60 cash-pay, or $0 after deductible for insured patients. Quest Diagnostics and LabCorp both operate in Cheyenne and Casper. Telehealth providers in Wyoming can order labs at these facilities or, for rural patients, may use at-home capillary potassium testing services, though traditional venous draws remain the clinical standard.

Lab costs add to total losartan therapy cost. A realistic annual budget for a stable patient on losartan monotherapy in Wyoming: $120 in drug costs ($10/month) plus $40, $120 in annual labs = $160, $240 total out-of-pocket per year at cash-pay rates. That figure positions losartan as one of the most cost-effective antihypertensive options available [19].


Comparing Losartan to Other ARBs Available in Wyoming

Losartan is not the only ARB. Valsartan, irbesartan, olmesartan, telmisartan, and candesartan are all generic and available in Wyoming. How does cost compare?

Valsartan 80 mg (30 tablets) runs $10, $15 at GoodRx prices in Wyoming. Irbesartan 150 mg runs $12, $18. Olmesartan 20 mg runs $15, $25. Telmisartan 40 mg, which has the longest half-life in the class (24 hours, less susceptible to missed-dose blood pressure spikes), runs $20, $30.

Losartan has the lowest generic price in the class largely because it was the first ARB approved (1995) and has had the longest period of generic competition. Its relatively short half-life (2 hours for losartan; 6 to 9 hours for its active metabolite EXP3174) means strict once-daily adherence matters more than with longer-acting ARBs [20].

The choice among ARBs should be clinical first, with cost as a tiebreaker. For a Wyoming patient with diabetic nephropathy, losartan or irbesartan have the strongest RCT evidence. The IDNT trial (N=1,715) demonstrated that irbesartan 300 mg reduced the primary composite renal endpoint by 20% vs. placebo (P<0.001) in patients with type 2 diabetes and nephropathy [21]. Losartan's RENAAL data and irbesartan's IDNT data are both Class A evidence supporting ARB use in this population [7].


Wyoming-Specific Resources and Programs

Wyoming has fewer safety-net pharmacy resources than larger states, but several national programs fill the gap.

Wyoming Department of Health, Medicaid PA process: For losartan prior authorization, submit Form DFS-103 with a letter of medical necessity. Processing takes 3, 5 business days for standard requests and 24 hours for urgent requests. Contact: (307) 777-7531.

SHIBA (State Health Insurance Benefits Advisors): Free counseling on Part D plan selection, appeals, and Extra Help/LIS applications. Particularly valuable for Wyoming seniors choosing between Part D plans where losartan tier placement varies. Website: wyomingshiba.org.

Wyoming 211: Connects patients to local charitable pharmacy programs and FQHC locations. Dial 2-1-1 from any Wyoming phone.

RxOutreach: A non-profit mail-order pharmacy that provides losartan to uninsured patients at $20 for a 90-day supply, approximately $6.67/month. Income eligibility is 300% FPL or below [22].


Frequently asked questions

How much does losartan cost in Wyoming?
Generic losartan costs roughly $10 per month at Wyoming retail pharmacies in 2026 when purchased cash-pay with a GoodRx or similar discount coupon. Brand-name Cozaar carries a list price near $80 per month, but virtually no patient needs to pay that rate given generic availability.
Does Wyoming Medicaid cover losartan?
Wyoming Medicaid does not currently list losartan on its preferred drug list. Coverage requires a prior authorization from Wyoming Department of Health, Division of Healthcare Financing. Prescribers can submit Form DFS-103 with a letter of medical necessity citing a clinical reason losartan is required over a PDL-preferred alternative. Dual-eligible Medicare-Medicaid patients typically access losartan through Medicare Part D at $0-$5 per month.
Is compounded losartan legal in Wyoming?
Yes. Compounded losartan is legal in Wyoming when a licensed 503A pharmacy prepares it under a valid patient-specific prescription from a licensed prescriber. The pharmacy must hold a current Wyoming pharmacy permit. Losartan is not on the FDA's demonstrably difficult to compound list, so 503A compounding is permissible where a clinical rationale for the customized formulation exists.
Can I get losartan via telehealth in Wyoming?
Yes. Wyoming law permits telehealth prescribing of losartan. No in-person visit is required for this non-controlled antihypertensive. A synchronous audio-video consultation with a licensed Wyoming prescriber, including review of blood pressure readings, renal function labs, and medication history, is sufficient to receive a valid prescription.
Which insurance plans cover losartan in Wyoming?
Most private insurance plans and Medicare Part D plans in Wyoming cover generic losartan at Tier 1 or Tier 2, typically at a $0-$10 copay. ACA marketplace plans through Blue Cross Blue Shield of Wyoming, Aetna, Cigna, and UnitedHealthcare all generally include it. If your plan places it in a higher tier, you can request a formulary exception in writing; insurers must respond within 72 hours for non-urgent requests.
What's the cheapest way to get losartan in Wyoming?
The cheapest approach for most uninsured Wyoming residents is a 90-day cash-pay fill at Costco Pharmacy in Cheyenne (no membership required for pharmacy use) with a GoodRx coupon, bringing cost to roughly $20-$27 per 90 days, or about $7-$9 per month. Patients below 300% FPL may qualify for RxOutreach at approximately $6.67 per month for a 90-day supply. Patients with qualifying compounding indications may access 503A compounded losartan at no direct cost through certain patient assistance arrangements.
Are there Wyoming losartan discount programs?
Yes. GoodRx, RxSaver, and NeedyMeds provide free coupons accepted at most Wyoming pharmacies. NeedyMeds also lists 340B-eligible clinics in Wyoming where losartan costs less than retail. Merck's patient assistance program covers branded Cozaar for patients below 300% FPL who lack adequate coverage. Wyoming 211 can connect patients to local charitable pharmacy programs.
How does the Merck savings card work in Wyoming?
Merck's patient assistance for Cozaar (brand losartan) is administered through partnership programs like the PAN Foundation for patients below 300% of the federal poverty level ($47,580 for a household of three in 2026) who lack adequate prescription coverage. The program provides branded Cozaar at no cost. Given that generic losartan is available for roughly $10 per month, this program is most relevant for patients who cannot tolerate excipients in the generic formulation or who require the brand for another documented clinical reason.
What labs do I need before starting losartan in Wyoming?
Before starting losartan, your provider should check a basic metabolic panel (BMP) to assess serum creatinine, potassium, and eGFR. Hyperkalemia risk rises significantly at eGFR below 45 mL/min and baseline potassium above 5.0 mEq/L. Quest Diagnostics and LabCorp both operate in Cheyenne and Casper; cash-pay BMP runs $20-$60. Telehealth providers can order these labs remotely.
What dose of losartan is typically prescribed?
For hypertension in adults, the standard starting dose is 50 mg once daily, with a range of 25-100 mg daily. Diabetic nephropathy is typically treated at 50-100 mg once daily. Pediatric patients aged 6 and older weighing more than 20 kg are dosed at 0.7 mg/kg/day up to 50 mg. Most Wyoming patients on generic losartan are prescribed 50 mg once daily, which corresponds to the roughly $10/month price point.
Can losartan be combined with other blood pressure medications?
Yes, losartan is commonly combined with thiazide diuretics (hydrochlorothiazide), calcium channel blockers (amlodipine), or beta-blockers. It must NOT be combined with ACE inhibitors or aliskiren due to increased risk of hypotension, hyperkalemia, and acute kidney injury. The ONTARGET trial confirmed no cardiovascular benefit from losartan plus ramipril, with greater harm compared to either agent alone.

References

  1. FDA. Losartan potassium (Cozaar) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s057lbl.pdf
  2. Centers for Disease Control and Prevention. Hypertension prevalence in the U.S. adult population. https://www.cdc.gov/bloodpressure/facts.htm
  3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://pubmed.ncbi.nlm.nih.gov/11937178/
  4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. https://pubmed.ncbi.nlm.nih.gov/29146535/
  5. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-871. https://pubmed.ncbi.nlm.nih.gov/27552619/
  6. Whelton PK, Carey RM. The 2017 American College of Cardiology/American Heart Association clinical practice guideline for high blood pressure in adults. JAMA Cardiol. 2018;3(4):352-353. https://pubmed.ncbi.nlm.nih.gov/29305595/
  7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. https://pubmed.ncbi.nlm.nih.gov/11565518/
  8. Centers for Medicare and Medicaid Services. Medicare Part D enrollment data by state, 2024. https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/mcradvpartdenroldata/partd
  9. U.S. Food and Drug Administration. Compounding laws and policies: 503A. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  10. U.S. Food and Drug Administration. Demonstrably difficult to compound list. https://www.fda.gov/drugs/human-drug-compounding/demonstrably-difficult-compound-drug-products-list
  11. U.S. Food and Drug Administration. Guidance for industry: telehealth prescribing of non-controlled substances. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
  12. U.S. Preventive Services Task Force. Hypertension in adults: screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening
  13. Centers for Medicare and Medicaid Services. Medicare Part D standard benefit parameters 2026. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin
  14. U.S. Department of Health and Human Services. 2026 federal poverty level guidelines. https://www.hhs.gov/poverty-guidelines
  15. NeedyMeds. Drug assistance programs and 340B resources. https://www.needymeds.org
  16. Palmer BF. Potassium binders for hyperkalemia in chronic kidney disease: diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin Proc. 2020;95(2):339-354. https://pubmed.ncbi.nlm.nih.gov/31685167/
  17. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559. https://pubmed.ncbi.nlm.nih.gov/18378520/
  18. American Diabetes Association. Standards of care in diabetes 2024: chronic kidney disease and risk management. Diabetes Care. 2024;47(Suppl 1):S219-S230. https://diabetesjournals.org/care/article/47/Supplement_1/S219/153960
  19. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-2097. https://pubmed.ncbi.nlm.nih.gov/22080794/
  20. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(Suppl 1):S73-S86. https://pubmed.ncbi.nlm.nih.gov/10854068/
  21. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). N Engl J Med. 2001;345(12):851-860. [https://pubmed.ncbi.nlm.nih.